Floatz logo

Aralast Np

Alpha1-antitrypsin Deficiency

ShirePhase 4 / ApprovedDormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Alpha1-antitrypsin Deficiency cohort.

Asset / SponsorPhaseRating
Alpha-1-Proteinase Inhibitor
Grifols Therapeutics LLC
Phase 4A
.ALPHA.-1 PROTEASE INHIBITOR
Grifols Therapeutics LLC
Phase 4A
NORMAL HUMAN SERUM ALBUMIN
Baxalta now part of Shire
Phase 4BBB
.ALPHA.-1 PROTEASE INHIBITOR
Grifols Therapeutics LLC
Phase 3BB
Alpha-1-Proteinase Inhibitor
Grifols Therapeutics LLC
Phase 3BB

View all 50 →

Same molecule, other indications

Aralast Np is also rated in:

chronic obstructive pulmonary diseaseDormant
CC
Indicative ·
47 / 100
View asset →
type 1 diabetes mellitusDormant
CC
Indicative ·
40 / 100
View asset →
diabetes mellitusDormant
C
Indicative ·
32 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →